Introduction
============

Cervical cancer is the most common female malignancy worldwide ([@b1-or-0-0-7388],[@b2-or-0-0-7388]). The incidence and mortality rates associated with cervical cancer are particularly higher in developing countries ([@b3-or-0-0-7388],[@b4-or-0-0-7388]). It has been estimated that 9.89/100,000 cervical cancer cases and 3.05/100,000 cancer-related deaths occurred in China in 2015 ([@b5-or-0-0-7388]). Almost all cervical cancers are caused by persistent infection with high-risk human papillomavirus (HPV), most commonly, HPV16 and HPV18 ([@b6-or-0-0-7388]--[@b8-or-0-0-7388]).

During carcinogenesis, immune checkpoint pathways are often exploited to evade immune surveillance ([@b9-or-0-0-7388],[@b10-or-0-0-7388]), particularly the development of cervical cancer. Hepatitis A virus cellular receptor 2 (HAVCR2) is also known as T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) ([@b11-or-0-0-7388]--[@b13-or-0-0-7388]). The most important role of Tim-3 is to negatively regulate Th1 immunity. Once Tim-3 binds to its ligand, galectin-9, Tim-3 inhibits Th1 and Th17 responses by hampering their expansion. The Tim-3/galectin-9 pathway contributes to the suppressive tumor microenvironment (TME) in the human body through Treg promotion upon T cell receptor (TCR) activation ([@b14-or-0-0-7388],[@b15-or-0-0-7388]). The DNA methylation of the Tim-3 promoter cooperates with lineage-specific transcription factors in the control of Th cell development ([@b16-or-0-0-7388],[@b17-or-0-0-7388]). Cao *et al* found that the expression of Tim-3 in tumor cells may be an independent prognostic factor for patients with cervical cancer; moreover, Tim-3 expression may promote metastatic potential in cervical cancers ([@b18-or-0-0-7388]). Liang *et al* found that decreased galectin-9 expression was inversely associated with the malignant potential or differentiation of cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma (SCC) as a differentiation biomarker ([@b19-or-0-0-7388]). Enhancer of zeste homolog 2 *(EZH2)* mRNA expression has been shown to be increased in cancer tissues compared to normal tissues, and the overexpression of EZH2 has been shown to be associated with the FIGO stage, histological type and lymph node metastasis in cervical cancer ([@b20-or-0-0-7388]). The inhibition of DNA (cytosine-5)-methyltransferase 3A (DNMT3A) promotes cervical cancer cell apoptosis, which further demonstrates that DNMT3A is involved in cervical carcinogenesis ([@b21-or-0-0-7388]). However, whether the abnormal methylation of the promoter regions of Tim-3/galectin-9 plays a role in the carcinogenesis of cervical cancer remains unclear.

In the present study, it was demonstrated that the promoter regions of *HAVCR2/LGALS9* were partially methylated, and that the protein expression of Tim-3/galectin-9 was increased when their methylation level decreased in accordance with the decreased DNMT3A expression. Our previous study found that HPV18 was the second most carcinogenic type of HPV in the Shaanxi Province of China ([@b22-or-0-0-7388]). Moreover, HPV18 E6 and E7 participate in the upregulation of EZH2 and H3K27me3 expression, which inhibits DNMT3A expression to downregulate the *HAVCR2/LGALS9* methylation levels. We thus hypothesized that the HPV18 oncoproteins E6 and E7 may play an important role in regulating the expression of Tim-3/galectin-9 in the immune microenvironment of cervical cancer through DNA methylation mediated by EZH2/H3K27me3/DNMT3A.

Materials and methods
=====================

### Patients and samples

A total of 24 cervical cancer tissue specimens, 24 matched peri-carcinomatous tissue specimens and 16 normal cervical tissue specimens were obtained from the First Affiliated Hospital of Xi\'an Jiaotong University between January, 2014 and December, 2017. All patients were diagnosed by two senior pathologists, and no patient had received chemotherapy or radiotherapy prior to surgery; details of the patient characteristics are presented in [Table I](#tI-or-0-0-7388){ref-type="table"}. Each patient enrolled in this study had volunteered and provided written informed consent. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi\'an Jiaotong University (G-272) in Shaanxi, China.

The cervical cancer samples were collected as previous described ([@b23-or-0-0-7388]). After the tissues were dissected, each sample was washed with sterilized PBS and stored at −80°C. All procedures were performed on ice.

### Data mining

Data obtained from the Gene Expression Profiling Interactive Analysis (GEPIA; <http://gepia.cancer-pku.cn/>) database was utilized to analyze the mRNA expression level of *HAVCR2/LGALS9* in cervical cancer and normal cervical tissues. The correlation between *HAVCR2* and *LGALS9* expression was determined by Pearson\'s correlation analysis. In addition, the association between a high and low *HAVCR2/LGALS9* mRNA expression with the overall survival (OS) of patients with cervical cancer was analyzed by Kaplan-Meier analysis, and the hazard ratio (HR) and log-rank P-value were also computed.

### HPV-DNA testing

HPV-DNA of 24 cervical cancer tissue samples was examined by polymerase chain reaction (PCR) and flow-through hybridization. In total, 21 HPV genotypes were qualitatively examined using the HPV genotyping test kit according to alkaline phosphatase system (HybriBio), including high-risk HPV types, namely HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, and common HPV types in China, namely HPV53, 66 and CP8304.

### Cell lines, culture conditions, overexpression and construction of cell lines with gene silencing

The two human cervical cancer cell lines, HeLa and C33A, were obtained from the Cell Bank, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai. All these cells were cultured in high-glucose Dulbecco\'s modified Eagle\'s medium (DMEM; HyClone) supplemented with 10% fetal bovine serum (FBS; Biological Industries) at 37°C in an atmosphere of 5% CO~2~. For the preparation of Plenti-CMV-puro-Dest vector containing the HPV18 E6/E7/E67 fragment, the HPV18 E6/E7/E67 fragment was cloned from the genomic DNA of the HPV18(+) cell line, HeLa. The DNA fragment was treated with *Kpn*1 and *Pst*1, and the target gene was then ligated into the entry vector pENTR-MCS. The plasmid Plenti-CMV-puro-Dest and pENTR-MCS recombination reactions were performed using LR Clonase II (Invitrogen; Thermo Fisher Scientific). Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific) was used to transfect the plasmid into the HPV(−) C33A cell line. The transduced cells were then selected with puromycin. Stably transduced cells were maintained in culture in the presence of puromycin. The cell lines were named C33A-18E6, C33A-18E7, and C33A-18E6/E7. The expression of the genes was determined by RT-qPCR.

The HeLa tumor cells were transfected with scramble, HPV18-E6, HPV18-E7, EZH2 and DNMT3A-specific siRNA (GenePharma), the following siRNA oligos for EZH2, HPV18-E6, HPV18-E7 and DNMT3A are listed in [Table II](#tII-or-0-0-7388){ref-type="table"}. The siRNAs were transfected using X-tremeGENE siRNA Transfection Reagent (Roche), and the transfected cells were analyzed for HPV18-E6, HPV18-E7, EZH2 and DNMT3A expression levels by RT-qPCR and western blot analysis. All cell lines were named 18E6-siRNA, 18E7-siRNA, 18E6/E7-siRNA, EZH2-siRNA and DNMT3A-siRNA.

### 5-Aza-2′-deoxycytidine (5-Aza-CdR) treatment

A total of 1.0×10^5^ HeLa and C33A cells per well were cultured separately in 6-well plates in DMEM with 10% FBS. After 24 h, the medium was replaced with fresh medium containing 0, 2.5 or 5 µM 5-Aza-CdR (Sigma-Aldrich; Merck KGaA). The medium containing 5-Aza-CdR was replaced every 24 h during a 72-h period, as previously described ([@b23-or-0-0-7388]).

### DNA extraction, bisulfite modification and methylation- specific PCR (MS-PCR)

Genomic DNA was isolated from the cells and tissues using a Takara Mini BEST Universal Genomic DNA Extraction kit (Takara) according to the manufacturer\'s instructions. DNA modification was performed as previously described ([@b23-or-0-0-7388]). A total of 500 ng of the extracted DNA was bisulfite-modified with the EZ DNA Methylation-Gold™ kit (Zymo Research). Modified DNA templates were used for MS-PCR with Zymo TaqTM PreMix (E2003; Zymo Research) following the instructions of the manufacturer. The online software MethPrimer (<http://www.urogene.org/methprimer/>) profiled CpG islands in the region that is located from −2,000 to −200 bp upstream of ATG in the *HAVCR2*/*LGALS9* promoters. One pair of primers was designed to amplify the *HAVCR2/LGALS9* promoter regions. The primer pairs used for MS-PCR are listed in [Table II](#tII-or-0-0-7388){ref-type="table"}. The thermocycling conditions were as follows: 95°C for 10 min and 40 cycles of 95°C for 30 sec. The annealing temperature for the methylated primer pairs of *HAVCR2* and *LGALS9* was 60°C, respectively, while that for the unmethylated primer pairs was 55°C and 56.3°C, respectively for 30 sec and 72°C for 30 sec, followed by an incubation step at 72°C for 7 min. The MS-PCR products were separated on a 2% agarose gel, stained with Gelview and visualized under ultraviolet illumination (Bio-Rad). Methylation level was calculated by the ratio of methylated and unmethylated levels. The calculation method was as follows: Methylation(M)=M/(M + U); unmethylation=U/(M + U). The grey value of each band represented its relative expression and was measured using ImageJ software. Each reaction was performed in triplicate.

### RNA extraction and reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from cells using TRIzol Reagent (Life Technologies; Thermo Fisher Scientific) according to the manufacturer\'s instructions and as previously described ([@b24-or-0-0-7388]). The RNA was then subjected to reverse transcription with a cDNA PrimeScript™ RT Master Mix (Takara). The primers used for qPCR are listed in [Table II](#tII-or-0-0-7388){ref-type="table"}. qPCR was carried out using SYBR-Green II Premix (Takara) by a two-step amplification procedure according to the manufacturer\'s protocol. The reaction conditions were as follows: 95°C for 30 sec, 40 cycles of 95°C for 5 sec and 60°C for 30 sec,72°C for 5 sec. We used the cycle threshold (CT) as the representative point. *GAPDH* was used as an internal reference gene. The relative expression of HPV18 *E6* and *E7* in each group (fold change compared with the control) was calculated using the formula: RQ=2^−∆∆Cq^ ([@b25-or-0-0-7388]). Each reaction was performed in triplicate.

### Western blot analysis

The cells were harvested in RIPA lysis buffer containing 1 mM protease inhibitor cocktail and 1 mM PMSF. The protein determination was assessed using a BCA detection kit (Beyotime Biotechnology, China). Proteins were resolved by 12% SDS-PAGE and electroblotted onto a polyvinylidene fluoride membrane (Millipore), 40 µg of protein loaded per lane, which was blocked for 1 h at room temperature in 5% skim milk, 1X TBS, 0.1% Tween-20. After blocking, the membrane was incubated with primary antibodies overnight at 4°C followed by incubation with HRP-conjugated secondary antibodies for 1 h at room temperature. The antibodies used were as follows: Rabbit polyclonal antibody against human Tim-3 (1:500 dilution, ab185703; Abcam), rabbit polyclonal antibody against human galectin-9 (1:100 dilution, ab123712; Abcam), mouse monoclonal antibody against human DNMT3A (1:200 dilution, sc-365769; Santa Cruz Biotechnology), rabbit monoclonal antibody against human EZH2 (1:1,000 dilution, 5246; Cell Signaling Technology), rabbit monoclonal antibody against human H3K27me3 (1:1,000 dilution, 9733; Cell Signaling Technology), mouse monoclonal antibody against HPV18 E6 (1:250 dilution, NB100-2729; Novus Biologicals) and mouse monoclonal antibody against HPV18 E7 (1:250 dilution, NB110-17215; Novus Biologicals), β-actin mouse monoclonal antibody (1:500 dilution, 60008-1-lg; Proteintech). The secondary antibodies were as follows: HRP-conjugated rabbit anti-mouse IgG (1:5,000 dilution, D110273-0100; BBI Life Sciences), HRP-conjugated goat anti-rabbit IgG (1:5,000 dilution, D110058; BBI Life Sciences). All antibodies were diluted by 1X TBST. The chemiluminescence signal was detected following incubation with enhanced chemiluminescence reagent (Millipore, Mass). The grey value of each band was measured with ImageJ software (1.47v).

### Chromatin immunoprecipitation (ChIP) assay and ChIP-qPCR

ChIP assays were carried out using the Simple ChIP Enzymatic Chromatin IP kit (9003; Cell Signaling Technology). Anti-H3K27me3 antibody (1:50 dilution, 9733; Cell Signaling Technology), anti-EZH2 antibody (1:100 dilution, 5246; Cell Signaling Technology), anti-DNMT3A antibody (1:50 dilution, ab2850; Abcam), anti-E2F-1 antibody (1:100 dilution, 3742; Cell Signaling Technology), anti-histone H3 antibody (1:50 dilution, 4620; Cell Signaling Technology), anti-IgG antibody (1:1,000 dilution, 2729; Cell Signaling Technology) and anti-FOXM1 antibody (1:100 dilution, 20459; Cell Signaling Technology) were used according to the manufacturer\'s instructions. The antibodies were incubated overnight at 4°C. The *DNMT3A, EZH2* and *HAVCR2/LGALS9* promoters DNA were detected by RT-qPCR using the promoter DNA-specific primers listed in [Table II](#tII-or-0-0-7388){ref-type="table"}. RT-qPCR was performed as described above. IgG was used as a negative control and histone H3 was used as a positive control.

### Co-immunoprecipitation (co-IP) assays

Immunoprecipitation was carried out to assess the interaction between EZH2, DNMT3A and HPV18 E6 and E7. After harvesting the total protein from the HeLa cells, the supernatants were incubated overnight at 4°C with rabbit anti-EZH2 (1:300 dilution, 5246; Cell Signaling Technology) and rabbit anti-DNMT3A (1:50 dilution, ab13888; Abcam) and protein G-Dynabeads (Thermo Fisher Scientific) were then conjugated to EZH2 and DNMT3A. The samples were then electrophoresed through gradient 12% SDS-polyacrylamide gels and transferred to membranes that were probed with mouse anti-HPV18 E6 and E7 antibodies, respectively (1:250 dilution; Novus Biologicals, NB100-2729/NB110-17215) and antibodies were incubated overnight at 4°C. This was followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The secondary antibodies: HRP-conjugated rabbit anti-mouse IgG (1:5,000 dilution, D110273-0100; BBI Life Sciences), HRP-conjugated goat anti-rabbit IgG (1:5,000 dilution, D110058; BBI Life Sciences). All antibodies were diluted using 1X TBST. Western blot analysis was performed as described above.

### Statistical analysis

Statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software). A paired t-test and one-way ANOVA were carried out on samples within groups, Dunnett\'s test was used as the post hoc test after one-way ANOVA. A P-value \<0.05 was considered to indicate a statistically significant difference. The data are presented as the means ± standard error of the mean (SEM). All experiments were independently repeated at least thrice, with consistent results.

Results
=======

### Protein expression of Tim-3/galectin-9 is increased in cervical cancer tissues, and the gene methylation level is decreased

The protein expression of Tim-3/galectin-9 in the 24 cervical cancer tissues, 24 matched pericarcinomatous tissues and 16 normal cervical tissues was detected by western blot analysis. Compared to that in normal cervical tissues, the average relative expression of Tim-3/galectin-9 was higher in the cervical cancer and pericarcinomatous tissues, although no significant difference was observed between the tumor tissues and pericarcinomatous tissues ([Fig. 1A-C](#f1-or-0-0-7388){ref-type="fig"}). The relative protein expression of Tim-3/galectin-9 in the HPV-positive cervical cancer tissues was higher than that in the HPV-negative cervical cancer tissues ([Fig. 1D](#f1-or-0-0-7388){ref-type="fig"}). Moreover, Tim-3 is encoded by *HAVCR2*, and galectin-9 is encoded by *LGALS9*. Using the GEPIA database (<http://gepia.cancer-pku.cn/>), we compared the mRNA expression of *HAVCR2/LGALS9* between the cervical cancer and normal cervical samples. The results indicated that the average mRNA expression levels of *HAVCR2* and *LGALS9* were higher in the cancer than in the normal cervical samples ([Fig. 1E](#f1-or-0-0-7388){ref-type="fig"}). We then investigated the effects of *HAVCR2/LGALS9* on patient prognosis using the GEPIA database. In particular, an increased *LGALS9* expression was associated with a poor overall survival (OS). Of note, no significant association was observed between the expression of *HAVCR2* and patient prognosis by the GEPIA database ([Fig. 1F](#f1-or-0-0-7388){ref-type="fig"}). Furthermore, *HAVCR2* positively correlated with *LGALS9* (r=0.26, P\<0.05) ([Fig. 1G](#f1-or-0-0-7388){ref-type="fig"}). In addition, the results of immunohistochemical analysis revealed that Tim-3 and galectin-9 were expressed in the tumor cells of the cervical cancer tissues ([Fig. 1H](#f1-or-0-0-7388){ref-type="fig"}). Furthermore, Tim-3 and galectin-9 were expressed in the HeLa and C33A cells ([Fig. 1I](#f1-or-0-0-7388){ref-type="fig"}).

Further experiments revealed that the *HAVCR2/LGALS9* promoters in 9 cervical cancer tissues and 9 normal cervical tissues displayed a hypermethylated status in normal cervical tissues compared with cervical cancer tissue samples, possibly leading to the inhibition of gene expression ([Fig. 1J and K](#f1-or-0-0-7388){ref-type="fig"}). Taken together, these results suggest that Tim-3/galectin-9 expression is increased in cervical cancer tissues.

### Methylation status in the promoter regions of HAVCR2/LGALS9 in cervical cancer cell lines

The online software, MethPrimer, profiled CpG islands in the region that is located from −2,000 to −200 bp upstream of ATG and the transcription starts site (TSS) in the *HAVCR2/LGALS9* promoters ([Fig. 2A](#f2-or-0-0-7388){ref-type="fig"}). One pair of primers was designed to amplify the *HAVCR2/LGALS9* promoter regions. MS-PCR analysis revealed that these regions upstream of ATG were partially methylated in the HeLa and C33A cells ([Fig. 2B](#f2-or-0-0-7388){ref-type="fig"}).

The mRNA expression level of *HAVCR2/LGALS9* in the HeLa and C33A cell lines following treatment with the DNA-demethylating reagent, 5-Aza-CdR, was determined to identify whether the methylation status in the promoter regions regulates the expression of *HAVCR2/LGALS9* genes at the transcriptional level. The results suggested that the mRNA expression of *HAVCR2/LGALS9* in the HeLa and C33A cells increased in a dose-dependent manner following cellular DNA demethylation ([Fig. 2C and D](#f2-or-0-0-7388){ref-type="fig"}). These findings illustrate that *HAVCR2/LGALS9* expression was reversed by 5-Aza-CdR, which promoted the expression of the *HAVCR2/LGALS9* genes at the transcriptional level.

### Methylation levels in the promoter regions of HAVCR2/LGALS9 are regulated by DNMT3A in cervical cancer cell lines

Following the knockdown of DNMT3A by siRNA, the expression level of Tim-3/galectin-9 was increased ([Fig. 3A and B](#f3-or-0-0-7388){ref-type="fig"}), and in turn, the degree of methylation of the genes encoding these proteins was decreased ([Fig. 3C and D](#f3-or-0-0-7388){ref-type="fig"}). These results suggest that DNMT3A plays an important role in regulating Tim-3/galectin-9 expression. To confirm this causal association, we performed ChIP analysis to evaluate the mechanisms underlying the DNA methylation-mediated regulation of Tim-3/galectin-9. ChIP analysis revealed the enhanced binding of DNMT3A ([Fig. 3F and H](#f3-or-0-0-7388){ref-type="fig"}) to the *HAVCR2/LGALS9* promoters ([Fig. 3E and G](#f3-or-0-0-7388){ref-type="fig"}) in the HeLa cells. Taken together, the results indicated that DNMT3A downregulated expression of the negative costimulatory molecules Tim-3/galectin-9 by upregulating the *HAVCR2/LGALS9* methylation levels in cervical cancer.

### EZH2 and H3K27me3 suppress DNMT3A expression in HeLa cells

The protein expression of EZH2, H3K27me3 and DNMT3A was detected by western blot analysis in 24 cervical cancer tissues, 24 matched pericarcinomatous tissues and 16 normal cervical tissues. The average relative expression levels of EZH2 and H3K27me3 were higher in the cervical cancer tissues than the controls, and DNMT3A expression was lower in the cancer tissues ([Fig. 4A and B](#f4-or-0-0-7388){ref-type="fig"}).

H3K27me3 expression was downregulated and DNMT3A expression was upregulated when EZH2 was knocked down by siRNA in the HeLa cells ([Fig. 4C](#f4-or-0-0-7388){ref-type="fig"}). Moreover, the methylation levels of the *HAVCR2/LGALS9* genes were upregulated ([Fig. 4D and E](#f4-or-0-0-7388){ref-type="fig"}), and the expression of Tim-3/galectin-9 was downregulated ([Fig. 4F](#f4-or-0-0-7388){ref-type="fig"}). H3K27me3 can thus regulate the methylation level of *HAVCR2/LGALS9* by altering the expression of DNMT3A.

EZH2 targets H3K27me3 as part of polycomb repressive complex 2 (PRC2), and its increased expression has been linked to a number of malignancies, with the highest EZH2 protein levels being associated with advanced disease and a poor prognosis ([@b27-or-0-0-7388]). In this study, in a screen for epigenetic mechanisms that regulate DNMT3A expression in HeLa cells, ChIP analysis revealed that the HeLa cells exhibited the highest EZH2 and H3K27me3 densities in a region upstream of the transcription initiation region ([Fig. 4G](#f4-or-0-0-7388){ref-type="fig"}). EZH2 and H3K27me3 negatively regulated the expression of DNMT3A by acting on the −1,000 to +1 region in the promoter of *DNMT3A* ([Fig. 4H and I](#f4-or-0-0-7388){ref-type="fig"}). These results suggest that EZH2 and H3K27me3 can alter the expression of the negative costimulatory molecules Tim-3/galectin-9 by synergistically regulating the expression of DNMT3A.

### HPV18 oncoproteins E6/E7 can alter the methylation and expression level of Tim-3/galectin-9 in cervical cancer cells

The mRNA expression of HPV18 E6 and E7 was increased following the overexpression of HPV18 E6 and E7 ([Fig. 5A](#f5-or-0-0-7388){ref-type="fig"}). The protein expression of DNMT3A was decreased when HPV18 E6 and/or E7 were overexpressed in the C33A cells ([Fig. 5C](#f5-or-0-0-7388){ref-type="fig"}). At the same time, the knockdown of E6 and/or E7 in the HeLa cells significantly decreased HPV18 E6 and E7 expression ([Fig. 5B](#f5-or-0-0-7388){ref-type="fig"}). In addition, the knockdown of E6 and/or E7 in the HeLa cells increased DNMT3A protein expression ([Fig. 5D](#f5-or-0-0-7388){ref-type="fig"}). These results revealed that HPV18 E6 and/or E7 can lead to a reduction in DNMT3A expression. Co-IP assay also revealed that neither HPV18 E6 nor E7 combined with DNMT3A directly ([Fig. 5E](#f5-or-0-0-7388){ref-type="fig"}).

Furthermore, the data revealed that HPV18 oncoproteins E6 and/or E7 downregulated the methylation level of *HAVCR2/LGALS9* significantly ([Fig. 5F](#f5-or-0-0-7388){ref-type="fig"}), and these altered methylation levels contributed to an increased Tim-3/galectin-9 expression among the cell lines with the overexpression of the HPV18 oncoproteins, E6 and/or E7, compared to the C33A cells ([Fig. 5H](#f5-or-0-0-7388){ref-type="fig"}). The knockdown of E6 and/or E7 yielded the opposite results in the HeLa cells ([Fig. 5G and I](#f5-or-0-0-7388){ref-type="fig"}). These results suggest that the HPV18 E6/E7 oncoproteins reduce the methylation level of the *HAVCR2/LGALS9* promoters and in turn promote translation of the protein products.

### HPV18 oncoproteins E6/E7 participate in the regulation of EZH2 and H3K27me3

EZH2 participates in H3K27me3-mediated gene silencing ([@b27-or-0-0-7388],[@b28-or-0-0-7388]). In this study, the EZH2 and H3K27me3 protein levels were strongly decreased when HPV18 oncoproteins were knocked down in the HeLa cells, and the overexpression of HPV18 E6 or/and E7 led to an increase in EZH2 and H3K27me3 expression ([Fig. 6A and B](#f6-or-0-0-7388){ref-type="fig"}). The expression of EZH2 and H3K27me3 in the HeLa cells was higher than that in the C33A cells ([Fig. 6C](#f6-or-0-0-7388){ref-type="fig"}). These results suggest that EZH2 and H3K27me3 are novel activation targets of HPV18 oncogenes.

However, the expression of HPV oncoproteins E6 or E7 was not altered when EZH2 was knocked down in the HeLa cells ([Fig. 6D](#f6-or-0-0-7388){ref-type="fig"}). Co-IP assays revealed that neither HPV18 E6 nor HPV18 E7 bound EZH2 directly ([Fig. 6E](#f6-or-0-0-7388){ref-type="fig"}). E6 oncoprotein induces FOXM1 expression via the MZF1/NKX2-1 axis in HPV-associated tumorigenesis ([@b29-or-0-0-7388]). The viral oncoprotein HPV E7 targets pRb, and the pRb/E2F-1 pathway directly regulates Kv10.1 transcription during G2/M ([@b30-or-0-0-7388]--[@b32-or-0-0-7388]). E2F-1 is enriched at proximal promoter of *EZH2* in MCF-7 cells ([@b33-or-0-0-7388]). FOXM1 is enriched on the promoter of *EZH2* in HCT116 cells ([@b34-or-0-0-7388]). In this study, in a screening for the epigenetic mechanisms that regulated EZH2 expression in HeLa cells, ChIP analysis revealed that the highest FOXM1 and E2F-1 density was found in a region upstream of the transcription initiation region in HeLa cells ([Fig. 6F](#f6-or-0-0-7388){ref-type="fig"}). It has also been shown that FOXM1 and E2F-1 regulates the expression of EZH2 by acting on the −1,000 to +1 region of the *EZH2* promoter ([Fig. 6G and H](#f6-or-0-0-7388){ref-type="fig"}). Moreover, ChIP analysis did not reveal the enhanced binding of FOXM1 and E2F-1 ([Fig. 6I and J](#f6-or-0-0-7388){ref-type="fig"}) to the *DNMT3A* promoters in the HeLa cells. Taken together, these findings suggest that HPV18 E6 and E7 promote EZH2 and H3K27me3 expression through the interaction of FOXM1 and E2F-1 with the promoter region of EZH2, and inhibit DNMT3A expression.

Discussion
==========

Epigenetic alterations, such as DNA methylation are essential for the carcinogenesis of cervical cancer, which results in the activation or exclusion of certain genes ([@b35-or-0-0-7388],[@b36-or-0-0-7388]). Cicchini *et al* ([@b37-or-0-0-7388]) found that HPV infection distinctly altered the methylation patterns in HPV-associated cancer, and that HPV E7-dependent promoter hypermethylation led to the downregulation of the chemokine CXCL14 and the suppression of antitumor immune responses. Epigenetically regulated cytokines mediate the expression of tumor-associated genes and manipulate their biological role in cancer ([@b38-or-0-0-7388]--[@b40-or-0-0-7388]).

The Tim-3/galectin-9 pathway, which plays a pivotal role in immune regulation, is differentially regulated in a variety of tumors and is a potential therapeutic target. Tim-3 and galectin-9 have been found to be significantly overexpressed in gastric cancer ([@b41-or-0-0-7388]). Additionally, high Tim-3 and low galectin-9 expression levels have been shown to be associated with a poor prognosis of patients with esophageal squamous cell carcinoma ([@b42-or-0-0-7388]). A higher expression level of Tim-3 has been shown to be positively associated with a shorter progression-free survival of patients with clear cell renal cell carcinoma ([@b43-or-0-0-7388]). Patients with glioma with a high expression of galectin-9 have been shown to exhibit a worse overall survival ([@b44-or-0-0-7388]).

In this study, the expression level of Tim-3/galectin-9 was higher in human cervical cancer samples than in normal cervical tissue. The high expression of *LGALS9*, but not *HAVCR2* was negatively associated with overall survival. Thus, it can be considered that the increased expression of secreted galectin-9 from cancer cells binds with Tim-3, causing immunosuppression in the tumor microenvironment; this leads to a poor overall survival in cervical cancer patients, suggesting that Tim-3 and galectin-9 promote the occurrence and development of cervical cancer. The levels of Tim-3 and galectin-9 were similar in cancer and para-cancerous tissues; thus, the role of Tim-3 and galectin-9 in paracancerous tissues requires further research, which is a limitation of the present study.

We found that there was partial methylation in the promoter regions of the *HAVCR2/LGALS9* genes, which encode negative costimulatory molecules Tim-3/galectin-9 in HeLa and C33A cells and in cervical cancer tissues; these methylation patterns in cancer cells could be reversed by 5-Aza-CdR treatment, leading to an upregulated Tim-3/galectin-9 expression. Tim-3/galectin-9 expression was promoted and the methylation levels of the CpG island in the *HAVCR2/LGALS9* promoters were reduced when DNMT3A was knocked down. ChIP analysis revealed that DNMT3A directly bound to the *HAVCR2/LGALS9* promoter regions in HeLa cells.

EZH2 is an essential catalytic subunit of PRC2, which silences gene expression by generating a methylated epigenetic mark at H3K27me3 ([@b27-or-0-0-7388],[@b45-or-0-0-7388],[@b46-or-0-0-7388]). DNMT3A cooperates with EZH2, and H3K27me3 contributes to the transcriptional regulation of gene expression ([@b47-or-0-0-7388]--[@b49-or-0-0-7388]). A number of epigenetic alterations occur in cellular genomes during HPV-associated carcinogenesis, and these alterations include histone modifications ([@b50-or-0-0-7388]--[@b53-or-0-0-7388]). Some researchers have also demonstrated that EZH2, H3K27me3 and DNMT1 cooperatively orchestrate epigenetic modification of the *wwc1* gene promoter in breast cancer ([@b54-or-0-0-7388]). In this study, we found that EZH2 and H3K27me3 was overexpressed and DNMT3A was expressed at low levels in cervical cancer tissues. Therefore, we hypothesized that EZH2 and H3K27me3 promote DNMT3A expression in cervical cancer. The downregulation of EZH2 inhibited H3K27me3 expression in HeLa cells and was accompanied by increased DNMT3A protein levels, demonstrating that DNMT3A is a downstream target gene of EZH2 and H3K27me3. Both EZH2 and H3K27me3 were enriched at CpG loci within the *DNMT3A* gene promoter in HeLa cells, as demonstrated by ChIP assays.

The knockdown of EZH2 and H3K27me3 expression was also associated with an increased *HAVCR2/LGALS9* methylation, which in turn caused the downregulation of Tim-3/galectin-9 expression. The EZH2-catalyzed trimethylation of H3K27 may be a prerequisite for promoter DNA methylation by recruiting DNMT3A. EZH2 and H3K27me3 synergistically regulated DNMT3A promoter expression and cooperatively orchestrated the epigenetic modification of the DNMT3A gene promoter.

HPV16 E6 and E7 can promote the secretion of soluble Tim-3 in oropharyngeal squamous cell carcinoma, resulting in a poor patient prognosis ([@b55-or-0-0-7388]). Notably, in this study, Tim-3/galectin-9 was expressed at higher levels in HPV-positive cancer tissues than in HPV-negative tissues. Altering the expression of HPV18 oncoproteins E6 and/or E7 also altered the Tim-3/galectin-9 protein expression level and the methylation status of their promoters. It has been suggested that HPV18 E6 and E7 regulate the expression of Tim-3/galectin-9 in cervical cancer by affecting the methylation level of the genes encoding these proteins. HPV18 E6 and E7 induced the downregulation of DNMT3A protein. The expression of Tim-3/galectin-9 was increased, and the methylation level of the CpG islands in the *HAVCR2/LGALS9* promoters was reduced when DNMT3A was knocked down. These results indicate that the HPV18 oncoproteins regulate Tim-3/galectin-9 expression through DNMT3A. However, the co-IP assay found that neither HPV18 E6 nor HPV18 E7 directly interacted with DNMT3A.

The results of this study illustrate that HPV18 E6 and/or E7 can elevate EZH2 expression in cervical cancer cells. In addition, the expression of EZH2 and H3K27me3 proteins in cervical cancer tissues was higher than that in normal tissues. However, the co-IP assay found that neither HPV18 E6 nor HPV18 E7 directly interacted with EZH2, and EZH2 knock down did not affect the expression of HPV18 E6 and E7. E6 oncoprotein can induce the expression of FOXM1 through the MZF1/NKX2-1 axis ([@b29-or-0-0-7388]). HPV mediates EZH2 expression through the transcriptional activation of the *EZH2* promoter via E7-mediated release of E2F factors from inhibitory pocket proteins ([@b56-or-0-0-7388]). The most well-studied cellular target of the viral oncogene E7 is pRb, and E2F-1 is the main target that is regulated by pRb. HPV E7 oncoprotein also leads to increased gene expression through the direct binding of the E2F-1 transcription factor to the gene promoter ([@b30-or-0-0-7388],[@b57-or-0-0-7388]--[@b59-or-0-0-7388]). EZH2 alterations in HPV16 E6/E7 HFKs lead to a loss of H3K27me3 and to the transcriptional depression of H3K27me3-targeted HOX genes ([@b51-or-0-0-7388]). In this study, we used a ChIP assay to illustrate that the transcription factors FOXM1 and E2F-1 can directly bind to the promoter of *EZH2*, but do not directly bind to the promoter of *DNMT3A*. Therefore, we assert the preliminary conclusion that EZH2 and H3K27me3 expression is regulated by HPV18 E6 and E7 through the transcription factors FOXM1 and E2F-1.

Our data reveal a key role for EZH2-H3K27me3-DNMT3A in regulating the costimulatory molecules Tim-3/galectin-9 in cervical cancer that involves the HPV18 oncoproteins E6/E7 ([Fig. 7](#f7-or-0-0-7388){ref-type="fig"}). EZH2 and H3K27me3 may represent therapeutic targets, and an epigenetic agent or inhibitor aimed at these proteins could decrease Tim-3/galectin-9 expression. The inhibition of the expression of EZH2 and H3K27me3 may be an effective approach with which to augment the efficacy of negative costimulatory molecules against cervical cancer. DNMT1 and DNMT3B are also associated with the methylation of genes. In this study, we focused on the role of DNMT3A in the regulation of Tim-3 and galectin-9, which is another limitation of this study; therefore, in the future, we aim to study the role of DNMT1 and DNMT3B in the regulation of Tim-3 and galectin-9 expression.
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###### 

Tim-3/galectin-9 protein and gene methylation levels in human cervical cancer tissues. (A) The protein levels of Tim-3 and galectin-9 in cervical cancer (Ca), para-carcinoma (Cap) (n=24) and normal cervical tissues (NC) (n=16) detected by western blot analysis. Blot images of 4 representative samples are shown from each group. (B) Densitometric analysis of Tim-3 and (C) galectin-9 protein levels in cervical cancer (n=24), para-carcinoma (n=24) and normal cervical tissues (n=16). (D) Gray level analysis of Tim-3/galectin-9 protein expression in HPV-positive (n=16) and -negative (n=8) cervical cancer tissues. (E) The mRNA expression level of *HAVCR2/LGALS9* in cervical cancer, analyzed by GEPIA. (M, methylated; U, unmethylated); methylated and unmethylated levels were quantified as M/M+U% and U/M+U%, respectively. \*P\<0.05; \*\*P\<0.01; ns, not significant. (F) The prognostic value of mRNA level of *HAVCR2/LGALS9* in cervical cancer patients, analyzed by GEPIA. (G) The correlation between *HAVCR2/LGALS9* in cervical cancer, analyzed by GEPIA. (H) Positive immunohistochemistry staining of Tim-3 and galectin-9 in representative cervical cancer samples. Magnification, ×400. (I) Tim-3 and galectin-9 expression in HeLa and C33A cells detected by western blot analysis. (J) Methylation level of *HAVCR2/LGALS9* promoter regions in cervical cancer (n=9) and normal cervical tissues (n=9) detected by methylation-specific PCR (MS-PCR). (K) Gray level analysis of *HAVCR2/LGALS9* methylation level in cervical cancer and normal cervical tissues. (M, methylated; U, unmethylated); methylated and unmethylated levels were quantified as M/M+U% and U/M+U%, respectively. \*P\<0.05; \*\*P\<0.01; ns, not significant.

![](or-42-06-2655-g00)

![](or-42-06-2655-g01)

![Detection of the methylation status in the promoter regions of *HAVCR2/LGALS9* in cervical cancer cell lines. (A) Predicted CpG islands in the promoter region of *HAVCR2/LGALS9*. Numbers indicate the positions in bp relative to the transcription start site. The blue region represents the CpG islands, and the red vertical bars are the CpG loci in these input sequences. (B) Detection of *HAVCR2/LGALS9* methylation status by methylation-specific PCR (MS-PCR) in HeLa and C33A cell lines; (M, methylated; U, unmethylated). (C) and (D) Relative expression of *HAVCR2/LGALS9* mRNA in HeLa and C33A cells following treatment with various concentrations of 5-Aza-CdR. \*P\<0.05; \*\*P\<0.01. 5-Aza-CdR, 5-aza-2′-deoxycytidine.](or-42-06-2655-g02){#f2-or-0-0-7388}

![DNMT3A regulates the expression of Tim-3/galectin-9 in cervical cancer cell lines. (A and B) DNMT3A-specific siRNA was transfected into HeLa cells, and the expression of DNMT3A and Tim-3/galectin-9 was detected by western blot analysis. β-actin protein was used as a loading control between lanes. (C) MS-PCR analysis was used to examine the methylation level of *HAVCR2/LGALS9* in HeLa cells in which DNMT3A was knocked down. (D) Gray level analysis of *HAVCR2/LGALS9* methylation levels in HeLa cells in which DNMT3A was knocked down (M, methylated; U, unmethylated); the methylated and unmethylated levels were quantified as M/M+U% and U/M+U%, respectively. (E and G) Schematic representation of the 4 regions of the *HAVCR2/LGALS9* promoters amplified in the chromatin immunoprecipitation (ChIP)-quantitative PCR (qPCR) experiment. (F and H) Chromatin was cross-linked, fragmented and immunoprecipitated with either IgG (mock) or anti-DNMT3A ChIP-grade antibody and the purified DNA was used to amplify with respective primer pairs for the indicated 4 regions in the *HAVCR2/LGALS9* promoters in qPCR. The enrichment of DNMT3A on *HAVCR2/LGALS9* promoters relative to IgG in HeLa cells, and H3 against *RPL30* was used as a positive control. \*P\<0.05; \*\*P\<0.01.](or-42-06-2655-g03){#f3-or-0-0-7388}

###### 

EZH2 and H3K27me3 regulate Tim-3/galectin-9 expression through DNMT3A. (A) The protein levels of EZH2, H3K27me3 and DNMT3A in cervical cancer (Ca), paracarcinoma (Cap) (n=24) and normal cervical tissues (NC) (n=16) detected by western blot analysis. Blot images of 4 representative samples are shown from each group. (B) Densitometric analysis of EZH2, H3K27me3 and DNMT3A protein levels in cervical cancer (n=24), paracarcinoma (n=24) and normal cervical tissues (n=16). (C and F) Western blot analysis of HeLa cells 48 h following transfection with siRNA against EZH2. β-actin protein was used as a loading control between lanes. (D) MS-PCR analysis was used to examine the methylation level of *HAVCR2/LGALS9*. (E) Gray level analysis of *HAVCR2/LGALS9* methylation levels in HeLa cells in which EZH2 was knocked down (M, methylated; U, unmethylated); the methylated and unmethylated levels were quantified as M/M+U% and U/M+U%, respectively. (G) Schematic representation of the 4 regions of the *DNMT3A* promoter amplified in the chromatin immunoprecipitation (ChIP)-quantitative PCR (qPCR) experiment. (H and I) Chromatin was cross-linked, fragmented and immunoprecipitated with either IgG (mock) or anti-EZH2 and anti-H3K27me3 ChIP-grade antibody and the purified DNA was used to amplify with respective primer pairs for indicated four regions in the *DNMT3A* promoters in qPCR. The enrichment of EZH2 and H3K27me3 on *DNMT3A* promoter relative to IgG in HeLa cells, and H3 against *RPL30* was used as a positive control. \*\*P\<0.01; ns, not significant.

![](or-42-06-2655-g04)
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![Function of HPV18 oncoproteins E6/E7 in the regulation of Tim-3/galectin-9 and DNMT3A expression in human cervical cancer cells. (A) and (B) mRNA levels in of HPV18 *E6/E7*-overexpressing C33A cells and of HPV18 *E6/E7*-knockdown HeLa cells. (C) and (D) C33A cells were transfected with 18E6/E7/E6/7 lentiviral vector, and HeLa cells were transfected with 18E6/E7/E6/7-specific siRNAs. Western blot analysis was then used to detect DNMT3A expression. (E) Co-IP assay was used to analyzed the incorporation between DNMT3A and HPV18 E6/E7. (F and G) The methylation level of the *HAVCR2/LGALS9* promoters was monitored by MS-PCR. Gray level analysis of *HAVCR2/LGALS9* methylation levels in cervical cancer cells (M, methylated; U, unmethylated); the methylated and unmethylated levels were quantified as M/M+U% and U/M+U%, respectively. (H and I) C33A cells were transfected with 18E6/E7/E6/7 lentiviral vector, and HeLa cells were transfected with 18E6/E7/E6/7-specific siRNAs. The expression of Tim-3/galectin-9 was determined by western blot analysis. \*\*P\<0.01.](or-42-06-2655-g06){#f5-or-0-0-7388}

![HPV18 oncoprotein E6/E7 alters the expression EZH2 and H3K27me3 in cervical cancer cells. (A and B) C33A cells were transfected with 18E6/E7/E6/7 lentiviral vector and HeLa cells were transfected with 18E6/E7/E6/7 specific siRNAs and western blot analysis was then used to detect EZH2 and H3K27me3 expression. (C) EZH2 and H3K27me3 expression in HeLa and C33A cells detected by western blot analysis. (D) Western blot analysis of the HPV18 E6/E7 protein level in HeLa cells following transfection with siRNAs against EZH2. (E) Co-IP assay was used to analyzed the incorporation between EZH2 and HPV18 E6/E7. (F) Schematic representation of the 4 regions of the *EZH2* promoter amplified in the chromatin immunoprecipitation (ChIP)-quantitative PCR (qPCR) experiment. (G and H) Chromatin was cross-linked, fragmented and immunoprecipitated with either IgG (mock) or anti-E2F-1 and anti-FOXM1 ChIP-grade antibody and the purified DNA was used to amplify with respective primer pairs for indicated four regions in the *EZH2* promoters in qPCR. The enrichment of E2F-1 and FOXM1 on *EZH2* promoter relative to IgG in HeLa cells, H3 against *RPL30* used as positive control. (I and J) Chromatin was cross-linked, fragmented and immunoprecipitated with either IgG (mock) or anti-E2F-1 and anti-FOXM1 ChIP-grade antibody and the purified DNA was used to amplify with respective primer pairs for the indicated 4 regions in the *DNMT3A* promoters in qPCR. The enrichment of E2F-1 and FOXM1 on *DNMT3A* promoter relative to IgG in HeLa cells, H3 against *RPL30* used as a positive control. \*\*P\<0.01; ns, not significant.](or-42-06-2655-g07){#f6-or-0-0-7388}

![The HPV18 pathway regulates Tim-3/galectin-9 through EZH2-H2K27me3-DNMT3A. HPV18 E6 and E7 regulates EZH2 through direct binding of FOXM1 and E2F-1 the *EZH2* promoter in order to activate EZH2 expression; in turn, H3K27me3 is upregulated. EZH2 and H3K27me3 directly interact with the *DNMT3A* promoter to downregulate its expression. When DNMT3A is decreased, the *HAVCR2/LGALS9* promoter region is also demethylated and Tim-3/galectin-9 expression is upregulated.](or-42-06-2655-g08){#f7-or-0-0-7388}

###### 

Patient characteristics (n=24).

  Item                        No.
  --------------------------- -----
  Age (years)                 
    ≤44                       10
    \>44                      14
  Clinical stages             
    Ia                        0
    Ib                        8
    IIa                       11
    IIb                       5
  Pathological pattern        
    Squamous cell carcinoma   21
    Adenocarcinoma            3
  Pathological grading        
    I                         1
    II                        19
    III                       4
  Lymph nodes metastasis      
    Yes                       3
    No                        21
  HPV infection               
    Positive                  16
    Negative                  8

###### 

Primer sequences.

  Name                     Application      Sequence
  ------------------------ ---------------- ---------------------------
  *DNMT3A*-ChIP-F1         ChIP-qPCR        ATCATCAGTAGGGCGGGGTGGCCAC
  *DNMT3A*-ChIP-R1         ChIP-qPCR        CTCCAATGCTTCCAGGTCCCTCCGT
  *DNMT3A*-ChIP-F2         ChIP-qPCR        TTGGAGAACCTCCCGAAGGAAAACC
  *DNMT3A*-ChIP-R2         ChIP-qPCR        GCCACCCTTTTAGCGTCACAGAACC
  *DNMT3A*-ChIP-F3         ChIP-qPCR        CGTTGGGGGGGCGGGTGCTGGGCTG
  *DNMT3A*-ChIP-R3         ChIP-qPCR        TGACTGGCACAGGACATGGCGTGCT
  *DNMT3A*-ChIP-F4         ChIP-qPCR        CATGGGGAAGGAGAACAGCCCCCAC
  *DNMT3A*-ChIP-R4         ChIP-qPCR        GCACTGGAAGACTGAAAGATTTCAT
  *EZH2*-ChIP-F1           ChIP-qPCR        GCTCACGCCTGTAATCCCAGCACTT
  *EZH2*-ChIP-R1           ChIP-qPCR        GGAGTTTCGCTCTGGTTGTCCAGGC
  *EZH2*-ChIP-F2           ChIP-qPCR        GGCTGAGGCATGAGAATCGCTTGAA
  *EZH2*-ChIP-R2           ChIP-qPCR        TGAGACGGAGTTTCGCTCTGGTTGT
  *EZH2*-ChIP-F3           ChIP-qPCR        GCCTGCACACCGCCTTCCTGAGAGG
  *EZH2*-ChIP-R3           ChIP-qPCR        GGGGTTCGCTGTAAGGGACGCCACT
  *EZH2*-ChIP-F4           ChIP-qPCR        CCACACGGCCAGTGGCGTCCCTTAC
  *EZH2*-ChIP-R4           ChIP-qPCR        CACGCAGAGTGCGCTCAGGGCTCGT
  *HAVCR2*-ChIP-F1         ChIP-qPCR        GTGGAAAAAATCTGTCACTTAGGGG
  *HAVCR2*-ChIP-R1         ChIP-qPCR        ATTTTTAGTAGAGACGGGGTTTCTC
  *HAVCR2*-ChIP-F2         ChIP-qPCR        CCTGTAATCCCAGCTACTCAGGAGG
  *HAVCR2*-ChIP-R2         ChIP-qPCR        CTTGTTCAATGTGTGTACTTCCCAT
  *HAVCR2*-ChIP-F3         ChIP-qPCR        CCCAATGCATTTAATGGCATAAATG
  *HAVCR2*-ChIP-R3         ChIP-qPCR        CAGCCACACTCCCATAACTGAGGTA
  *HAVCR2*-ChIP-F4         ChIP-qPCR        GGAACTCAACACTTTCTGATCATTC
  *HAVCR2*-ChIP-R4         ChIP-qPCR        GACTTTGACCTTCAAACTTCCAACT
  *LGALS9*-ChIP-F1         ChIP-qPCR        GGTAGAGTAAAATGTACAGATCCTG
  *LGALS9*-ChIP-R1         ChIP-qPCR        GCGAGACCTTGTCTCTACTAAAAAT
  *LGALS9*-ChIP-F2         ChIP-qPCR        TCAGCCTCCCAATGTGCTGAATTAC
  *LGALS9*-ChIP-R2         ChIP-qPCR        CCAGATCCAAACTTGACTTGAAGTG
  *LGALS9*-ChIP-F3         ChIP-qPCR        TCCTGTGGCCTAGCTCCTTTTTATT
  *LGALS9*-ChIP-R3         ChIP-qPCR        AGAAAAACTGCTTGGTGAGTTGTAA
  *LGALS9*-ChIP-F4         ChIP-qPCR        CACATATGTTTTCCTTTCTCTTGGG
  *LGALS9*-ChIP-R4         ChIP-qPCR        ACACCTGTGGTCTCAGCTACATGGG
  *HPV18*-E6-F             RT-qPCR          CAACACGGCGACCCTACAAG
  *HPV18*-E6-R             RT-qPCR          GCTGGATTCAACGGTTTCTGG
  *HPV18*-E7-F             RT-qPCR          ACATTTACCAGCCCGACG
  *HPV18*-E7-R             RT-qPCR          CAAAGGACAGGGTGTTCAGA
  *GAPDH*-F                RT-qPCR          GCACCGTCAAGGCTGAGAAC
  *GAPDH*-R                RT-qPCR          TGGTGAAGACGCCAGTGGA
  *HAVCR2*-ML              MS-PCR           TATAAAATGAGAAATTGGTCGGGCG
  *HAVCR2*-MR              MS-PCR           TTACAAACATATACCACCACCCCGA
  *HAVCR2*-UL              MS-PCR           GAAATTGGTTGGGTGTGGTGGTTAT
  *HAVCR2*-UR              MS-PCR           TATACCACCACCCCAAATAATTTTA
  *LGALS9*-ML              MS-PCR           TTTTCGAGATAGGTTTGCGATTTTG
  *LGALS9*-MR              MS-PCR           AATACCGACACCCTTCAATCACCAC
  *LGALS9*-UL              MS-PCR           GAGTTTTTGAGATAGGTTTGTGATT
  *LGALS9*-UR              MS-PCR           ATACCAACACCCTTCAATCACCACA
  *EZH2*-sense             Gene silencing   CGGCUUCCCAAUAACAGUATT
  *EZH2*-anti-sense        Gene silencing   UACUGUUAUUGGGAAGCCGTT
  *DNMT3A*-sense           Gene silencing   GCCAAGGUCAUUGCAGGAATT
  *DNMT3A*-anti-sense      Gene silencing   UUCCUGCAAUGACCUUGGCTT
  *HPV18*-E6-sense         Gene silencing   CGCAGAGAAACACAAGUAUTT
  *HPV18*-E6-anti-sense    Gene silencing   AUACUUGUGUUUCUCUGCGTT
  *HPV18*-E7-sense         Gene silencing   GUCACACAAUGUUGUGUAUTT
  *HPV18*-E7-anti-sense    Gene silencing   AUACACAACAUUGUGUGACTT
  Negative control-sense   Gene silencing   UUCUCCGAACGUGUCACGUTT
  Negative control-sense   Gene silencing   ACGUGACACGUUCGGAGAATT

ChIP, chromatin immunoprecipitation; RT-qPCR, reverse transcription-quantitative PCR; MS-PCR, methylation-specific-polymerase chain reaction; F, Forward primer; R, reverse primer; ML/UL, methylation/unmethylation forward primer; MR/UR, methylation/unmethylation backward primer.
